Maternal health R&D gaps: A test of African health system resilience

Through the Accra Declaration and the African Union Champion Roadmap on Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCAH) 2026–2030, African leaders have committed to ending preventable maternal deaths. Products such as heat-stable carbetocin and the Ellavi balloon tamponade show that maternal health tools can be designed for low-resource settings, and in Ellavi’s case, made in Africa. The critical question is whether global research and development is producing the maternal health tools African women need, and whether those tools can reach them in time.

The third report in the R&D Blindspots series from PATH and Impact Global Health answers: not yet. Drawing on R&D funding data, product pipelines, clinical trial records, and regulatory and manufacturing analysis, the report looks at four conditions that drive much of maternal and newborn death: postpartum hemorrhage, preeclampsia and eclampsia, maternal iron deficiency anemia, and preterm labor.

The findings show a field that is underfunded, fragile, and largely shaped outside the continent:

  • Sub-Saharan Africa accounts for 70% of global maternal deaths, yet R&D for these four conditions received just US$306 million between 2023 and 2025. That is around 1% of the global health R&D funding tracked by G-FINDER.
  • Two funders based outside the continent provided three-quarters of that funding, while industry contributed just 1%.
  • Three-quarters of preeclampsia diagnostics and 88% of preterm labor diagnostics need a laboratory. That limits their use in primary care, where African women receive antenatal care.
  • Only 0.3% of the US$38 billion in global health clinical trial funding tracked since 2007 went to trials that included pregnant and lactating women.
  • African institutions led just 22 of the 62 maternal health trials in sub-Saharan Africa.
  • Even proven products designed for African settings face slow regulatory, procurement, and manufacturing pathways, delaying their reach to women who need them.

This highlights a critical blindspot: neither the Accra Declaration nor the AU Champion Roadmap identifies the maternal health products or research priorities needed to meet its goals. Closing these R&D and access gaps is essential to delivering on the promise to end preventable maternal deaths and reach those goals.

The report identifies priority actions, including:

  • adding a priority list of maternal health products to Accra Declaration implementation plans, covering low-cost postpartum hemorrhage devices and point-of-care diagnostics;
  • making the inclusion of pregnant and lactating women the default in clinical trials that funders support;
  • using regulatory reliance and joint assessments to fast-track maternal health products already recommended by WHO; and
  • aggregating demand across borders through joint procurement and pooled forecasting, giving manufacturers the volume and predictability they need to invest.

Maternal Health R&D Gaps is the third publication in the Blindspots series, produced jointly by Impact Global Health and PATH. Launched at the International Conference on Public Health in Africa (CPHIA 2026) in Addis Ababa, the report underscores the urgency of closing maternal health R&D gaps.

Publication date: November 2026

Maternal health R&D gaps: A test of African health system resilience

1.3 MB PDF
View Resource